Related Experiment Video
Updated: Dec 5, 2025

05:19
Author Spotlight: Unraveling the Molecular Mechanisms in PCO and Fibrosis Following Cataract Surgery
Published on: December 1, 2023
1.5K
[Cataract surgery in megalocornea (case report)]
1Research Institute of Eye Diseases, Moscow, Russia.
Vestnik Oftalmologii
|October 16, 2020
Summary
The Haigis formula accurately calculated intraocular lens power for a patient with megalocornea, avoiding hyperopic refractive error. The patient experienced significant pseudoaccommodation after bilateral cataract surgery.
Area of Science:
- Ophthalmology
- Refractive Surgery
- Intraocular Lens (IOL) Calculation
Background:
- Megalocornea is a rare condition characterized by an enlarged cornea.
- Accurate intraocular lens (IOL) power calculation is crucial for achieving desired refractive outcomes after cataract surgery, especially in eyes with atypical anatomy like megalocornea.
Related Concept Videos
Angle Closure Glaucoma: Treatment
986
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
986
Open Angle Glaucoma: Treatment
859
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
859

